Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate

Investors looking for growth chances at fair prices often use screening methods that weigh several basic factors. The Affordable Growth method focuses on companies showing solid expansion ability while keeping good financial condition and earnings, all at prices that do not seem too high. This system tries to find businesses that mix growth traits with basic steadiness, possibly giving good returns for the risk taken. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) recently appeared from this kind of screening process, making a more detailed look at its investment case necessary.

Growth Path

Supernus Pharmaceuticals shows notable growth traits that fit well with affordable growth standards. The company's expansion numbers display both past power and encouraging future signs:

• Earnings Per Share rose 50.93% over the last year, pointing to solid recent results
• Sales have increased at an 11.00% yearly speed over recent years, showing steady top-line growth
• Future estimates point to a quickening, with EPS predicted to rise 18.47% each year and sales expected to go up 13.44% per year
• Both EPS and sales growth speeds are getting faster from past patterns, hinting at gaining speed

These growth measures are especially key for the affordable growth plan as they show the company is growing at a rate that might support higher prices, while the quickening pattern hints at a chance for continued better performance.

Price Assessment

The price view for Supernus shows a notable blend of standard and future-looking measures that back the affordable growth idea:

• Current P/E ratio of 15.96 sits much lower than the industry average of 24.85 and is notably under the S&P 500's 27.08 number
• Enterprise Value to EBITDA and Price/Free Cash Flow ratios are lower than about 82-85% of industry friends
• Future P/E of 23.83 matches closely with S&P 500 guesses but stays below industry future averages
• The company's very good earnings profile might support somewhat higher price multiples

This price setup is key for affordable growth investing as it hints the market may not be fully counting the company's growth chance, making a possible opening for investors who spot this difference early.

Earnings and Financial Condition

Beyond growth and price, Supernus displays basic strengths that offer key protections for growth-focused investors:

• Earnings rating of 8/10 shows strong business performance with Return on Assets of 4.67% and Return on Equity of 6.06%, both sitting in the top 15% of drug company friends
• Gross Margin of 89.87% puts the company in the industry's top group, showing strong price control and cost management
• Financial Condition score of 7/10 gains from no debt present and solid cash ratios
• Current Ratio of 2.58 and Quick Ratio of 2.43 show plenty of short-term money flexibility

These features are important within the affordable growth structure because strong earnings support continued spending in growth projects, while good financial condition lowers failure risk and offers steadiness during market drops.

Investment Points

Supernus Pharmaceuticals works in the competitive drug sector with a focus on central nervous system illnesses, selling products such as Qelbree, GOCOVRI, and Oxtellar XR. The company's specialized focus and market lineup provide the sales base supporting its growth path. The mix of fair price, solid growth chances, and good basic health makes SUPN worth a look for investors seeking growth at fair prices.

The company's detailed basic analysis report offers more details for those doing deeper checks. For investors interested in finding similar chances, other affordable growth picks can be located using this specific stock screening tool.

Disclaimer: This analysis is based on basic data and screening systems for information only. It does not form investment guidance, suggestion, or support of any security. Investors should do their own study and talk with money advisors before making investment choices. Past results do not ensure future outcomes, and all investments hold risk including possible loss of original money.